Oruka Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 855 OAK GROVE AVE., MENLO PARK, CA, 94025
Mailing Address 855 OAK GROVE AVE., MENLO PARK, CA, 94025
Phone 650-606-7910
Fiscal Year End 1231
EIN 363855489
Financial Overview
FY2024
$13.80M
Total Liabilities
$382.22M
Stockholders' Equity
$-3.87
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 16, 2026 | View on SEC |
Insider Trading
STRONG SELL 2 insiders
9 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.